The FDA on September 20, 2022, approved Sodium thiosulfate (PEDMARK®) to reduce the risk of ototoxicity associated with Cisplatin in pediatric patients 1 month and older with localized, non-metastatic solid tumors. PEDMARK® is a product of Fennec Pharmaceuticals Inc.
Bottom Ad
Advertisement
Subscribe
